Pharmacovigilance Risk Assessment Committee (PRAC): 10 - 13 March 2025, European Medicines Agency, Amsterdam, the Netherlands, from 10 March 2025 to 13 March 2025

Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 11, Status: Authorised

PSUSA/00010239/202408

Human medicines European public assessment report (EPAR): Firazyr, icatibant, Date of authorisation: 11/07/2008, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Ongentys, opicapone, Date of authorisation: 24/06/2016, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Zepatier, elbasvir,grazoprevir, Date of authorisation: 22/07/2016, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Cabazitaxel Accord, cabazitaxel, Date of authorisation: 28/08/2020, Revision: 7, Status: Authorised

Leveraging the power of data for public and animal health

Network Data Steering Group (NDSG)

Network Data Steering Group workplan 2025-2028